New class of non-β-lactam antibiotics to treat methicillin-resistant Staphylococcus aureus (MRSA)
A team of scientists have discovered a new class of antibiotics with 100% oral bioavailability to fight drug-resistant bacteria including MRSA
A team of scientists have discovered a new class of antibiotics with 100% oral bioavailability to fight drug-resistant bacteria including MRSA, a serious threat to public health.
This new class, called oxadiazoles, was discovered in silico screening and inhibits penicillin-binding protein 2a (PBP2a) and the biosynthesis of the cell wall which enable MRSA to resist other drugs.
What are the public health implications?
This new class, called oxadiazoles, was discovered in silico screening and inhibits penicillin-binding protein 2a (PBP2a) and the biosynthesis of the cell wall which enable MRSA to resist other drugs.
What are the public health implications?
- Contact Email
- [email protected]
- Issued By
- lorraine xu
- Country
- United States
- Categories
- Health
- Last Updated
- March 25, 2014